⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8562622 | 0.79 | — | — | |
| SCHEMBL4629837 | 0.77 | — | — | |
| SCHEMBL7046884 | 0.71 | — | — | |
| SCHEMBL969859 | 0.70 | TSHR (0.33) | — | |
| SCHEMBL8546188 | 0.70 | ALDH1A1 (0.31) | — | |
| SCHEMBL1934622 | 0.70 | HDAC2 (0.32) | — | |
| SCHEMBL8209626 | 0.70 | AKT1 (0.33) | — | |
| SCHEMBL10998680 | 0.70 | — | — | |
| SCHEMBL1051197 | 0.67 | — | — | |
| SCHEMBL10598572 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007119600-A9 | CARBAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008010601-A1 | NF- &kappav;B INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| EP-0944681-A1 | RADIATION-HARDENING COMPOSITIONS | Wacker-Chemie GmbH (DE) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998027174-A1 | RADIATION-HARDENING COMPOSITIONS | WACKER-CHEMIE GMBH (DE) | 1998-06-25 | — | — | WO | disclosed |